OpGen Stock Forecast, Price & News

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have decreased by 5.3% and is now trading at $1.96.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OpGen or view MarketBeat's top 5 stock picks.

Wall Street analysts have given OpGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OpGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OpGen is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for OpGen.

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Wednesday, November, 11th. The medical research company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04. OpGen had a negative return on equity of 181.57% and a negative net margin of 532.22%.
View OpGen's earnings history.

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen updated its third quarter 2020 Pre-Market earnings guidance on Thursday, October, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1-1 million, compared to the consensus revenue estimate of $1.6 million.

2 brokers have issued 1-year price targets for OpGen's stock. Their forecasts range from $5.65 to $5.65. On average, they anticipate OpGen's share price to reach $5.65 in the next twelve months. This suggests a possible upside of 188.3% from the stock's current price.
View analysts' price targets for OpGen.

OpGen saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 1,730,000 shares, a decrease of 18.8% from the October 15th total of 2,130,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is presently 0.6 days.
View OpGen's Short Interest.

Some companies that are related to OpGen include Progenity (PROG), Enzo Biochem (ENZ), Celcuity (CELC), Biocept (BIOC), Miragen Therapeutics (MGEN), AnPac Bio-Medical Science (ANPC), Psychemedics (PMD), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX), American Shared Hospital Services (AMS), Cancer Genetics (CGIX), CBA Florida (CBAI), PotNetwork (POTN), Zicix (ZICX) and First Choice Healthcare Solutions (FCHS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock is owned by many different retail and institutional investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.27%), Schonfeld Strategic Advisors LLC (0.27%) and Wedbush Securities Inc. (0.08%). Company insiders that own OpGen stock include Evan/ Fa Jones and NV In Liquidation Curetis.
View institutional ownership trends for OpGen.

OPGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold OpGen company stock in the last year include Evan/ Fa Jones, and NV In Liquidation Curetis.
View insider buying and selling activity for OpGen.

OPGN stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $1.96.

OpGen has a market capitalization of $44.08 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 38 workers across the globe.

The official website for OpGen is www.opgen.com.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (301) 869-9683 or via email at [email protected]